Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, 14080, Mexico
NCT Number: NCT04775563
Rheumatological diseases (RD) are an important group of different clinical entities and specific diseases that affect a significant proportion of the world population. In Mexico, the RD have a relevant representation in the adult population. COVID-19 vaccination has been proposed as a measure to contain the COVID-19 pandemic. The vaccines have been shown to be effective and reasonably safe in the population without significant risk factors, which has allowed their approval to attend the health emergency. At present, there is little scientific information that allows a solid recommendation on vaccination for COVID-19 in patients with RD, although most authorities have spoken in favor of vaccination in immunocompromised patients, as are a relevant number of patients with RD. However, it is desirable to achieve herd immunity to facilitate the impact of vaccination on the transmission of SARS-CoV-2 infection. For this, it is required that around 70% -80% of the target population be vaccinated, which implies not only access to the vaccine but also accepting to be vaccinated.
Vaccine hesitancy is defined as the delay or refusal to accept the vaccine when it is available by health services. Sometimes, they conceptualize it as a continuum and also includes the high demand from the population for the vaccine; In this continuum, there are variations in acceptance and rejection and multiple possible combinations, from acceptance with great concern about the decision to rejection of certain vaccines but not others. It is a complex, contextual, changing phenomenon, specific for each vaccine and the referred disease and probably influenced by cultural determinants.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
Mexico City, 14080, Mexico
The objectives are:
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
Time frame: At study inclusion
Identify the percentage of patients with rheumatic diseases that present COVID-19 vaccine hesitancy using the instrument developed by Freeman et al (translation, cultural adaptation, and validation performed)
Time frame: At study inclusion
Identify factors associated with COVID-19 vaccine hesitancy among rheumatic diseases patients using an instrument locally development
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Other
COVID-19 Vaccine Hesitancy Among Mexican Rheumatic Diseases Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04542031
COVID-19, Connective Tissue Diseases
Wolverhampton, West Midlands, United Kingdom
View Trial DetailsNCT04806113
Arthritis, Arthritis, Rheumatoid
Montreal, Quebec, Canada
View Trial DetailsNCT04924881
COVID-19, Coronaviridae Infections
Shatin, Hong Kong
View Trial DetailsNCT04939506
Behavior, COVID-19
New Orleans, Louisiana, United States
View Trial Details